Therapeutic Response

FGFR1 rearrangements status confers therapeutic sensitivity to Pemigatinib in patients with Lymphocytic Neoplasm.

Statements

Source and description
Pemazyre (pemigatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.